News

Researchers at the National Biologics Facility (NBF) at The University of Queensland will benefit from a substantial funding boost for COVID-19 research.

Congratulations to our 2020 AIBN Graduates 

Even before being awarded her PhD at the University of Queensland, Yun (Amy) Liu’s research had reached stratospheric heights.

The next critical phase for The University of Queensland’s COVID-19 vaccine, is underway – with the research effort moving out of the lab and into human trials. The vaccine has been developed by Professor Paul Young, Associate Professor Keith Chappell and Dr Dan Watterson who have been driving the program, housed at AIBN, jointly with Project Director, AIBN’s Professor Trent Munro.

A novel rapid cancer diagnostic technology with the potential to quickly and easily detect cancer has been licensed for further development.

The UQ vaccine uses the ‘molecular clamp’ technology developed by Professor Paul Young, Associate Professor Keith Chappell and Dr Dan Watterson who have been driving the program, housed at AIBN, jointly with Project Director, AIBN’s Professor Trent Munro.

Australian Institute for Bioengineering and Nanotechnology research has helped attract partnership that could revolutionise the manufacture and delivery of vaccines.

AIBN researchers have secured new funding to help the design of new nanomedicines, diagnostics and strengthen collaborative industry-partnered research projects.

AIBN researchers will help develop early and improved diagnostic tests to lift ovarian cancer survival rates with funding from the Medical Research Future Fund.

AIBN Director Professor Alan Rowan has been elected to the Australian Academy of Science.

A new program that aims to significantly improve supercapacitors will proceed after securing international backing.

AIBN researchers have developed a new way to produce nanoparticles that carry much higher drug concentrations.

The University of Queensland’s COVID-19 vaccine has passed another important milestone, showing the ability to raise high levels of antibodies that can neutralise the virus in early pre-clinical testing.

AIBN researchers have discovered that hard nanoparticles can enter human cells, including cancer cells, much more easily than soft ‘squishy’ nanoparticles. The findings will help to guide the design of more potent, highly targeted treatments for a range of diseases.

UQ’s Research Computing Centre (RCC) has, through some clever repurposing of decommissioned cloud computer parts, created a powerful new computer called Delena, which is housed at the Australian Institute for Bioengineering and Nanotechnology (AIBN).

Nanotechnology developed to detect cancer can also identify signals released by cancer cells, possibly resulting in earlier diagnosis and better treatment.

The development of next generation solar power technology that has potential to be used as a flexible ‘skin’ over hard surfaces has moved a step closer, thanks to a significant breakthrough at AIBN.

For patients with kidney failure, the ability to replace a damaged kidney with a healthy kidney grown from their own cells could be a life saver. Now, AIBN scientists have developed a remarkable new research tool that could help make this a reality.  

AIBN researchers could use a process developed to fight Hendra virus to help manufacture treatments for other potentially deadly disease.

UQ researchers in the AIBN labs have been asked to develop a vaccine for the recent coronavirus outbreak at unprecedented speed, using new technology.